Pernix Therapeutics is a specialty pharmaceutical company primarily focused on the sales, marketing, manufacturing and development of branded, generic and OTC pharmaceutical products. The Company manages a portfolio of branded products, including the recently acquired Hawthorn Pharmaceuticals’ product line. The Company’s branded products for the pediatrics market include CEDAX®, an antibiotic for middle ear infections, NATROBA™, a topical treatment for head lice marketed under an exclusive co-promotion agreement with ParaPRO, LLC, and a family of treatments for cough and cold (ZUTRIPRO®, BROVEX®, ALDEX® and PEDIATEX®). The Company’s branded products for gastroenterology include OMECLAMOX-PAK®, a 10-day treatment for H. pylori infection and duodenal ulcer disease, and REZYST™, a probiotic blend to promote dietary management. The Company also markets the branded product, SILENOR®, for the treatment of insomnia. The Company promotes its branded pediatric and gastroenterology products through its sales force. Pernix markets its generic products through its wholly-owned subsidiaries, Cypress Pharmaceutical and Macoven Pharmaceuticals. The Company’s wholly-owned subsidiary, Pernix Manufacturing, manufactures and packages products for the pharmaceutical industry in a wide range of dosage forms. Founded in 1996, the Company is based in Houston, TX.
PERNIX THERAPEUTICS TO REPORT FOURTH QUARTER AND FULL YEAR 2013 FINANCIAL RESULTS ON MARCH 17, 2014
PERNIX SIGNS AGREEMENT WITH OSMOTICA PHARMACEUTICAL CORP TO PROMOTE KHEDEZLA™ (DESVENLAFAXINE ER) TABLETS, 50 MG AND 100 MG FOR MAJOR DEPRESSIVE DISORDER
PERNIX CLOSES $65 MILLION INSTITUTIONAL INVESTMENT; AMENDS MIDCAP REVOLVER; MOVES TO RESHAPE BOARD OF DIRECTORS
Pernix Therapeutics’ family of branded prescription products are well-recognized and a highly prescribed portfolio of core marketed products. Our products are developed to meet the needs of patients and physicians by focusing on safe, unique and effective products for treating common medical conditions.
Our pediatric division has a solid track record in promoting the established brands of CEDAX® (ceftibuten) Suspension, CEDAX® (ceftibuten) Capsules and Natroba® (spinosad) Topical Solution. Pediatricians trust our products to treat their patients for conditions they see on a daily basis, including acute otitis media, asthma, allergies, upper respiratory ailments and lice.
Pernix’s line of primary care products offers the physician choices in treating common ailments of the adult patient. ZUTRIPRO® (hydrocodone bitartrate, pseudoephedrine HCl, chlorpheniramine maleate) Oral Solution, Silenor® (doxepin) Tablets, and Omeclamox-Pak® (omeprazole, clarithromycin, amoxicillin) are a few of the primary care products Pernix Therapeutics offers.
Pernix markets its generic products through its wholly-owned subsidiaries, Macoven Pharmaceuticals and Cypress Pharmaceutical. Sales of generic products represented 36% of the net revenues of Pernix for the year ended December 31, 2012. The generic product portfolios include the areas of antibiotics, respiratory care, dermatology, pain, gastroenterology, dental health and vitamins.